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With the current access to the whole genomes of various
organisms and the completion of the first draft of the human
genome, there is a strong need for a structure-function classi-
fication of protein families as an initial step in moving from
DNA databases to a comprehensive understanding of human
biology. As a result of the explosion in nucleic acid sequence
information and the concurrent development of methods for
high-throughput functional characterization of gene products,
the genomic revolution also promises to provide a new para-
digm for drug discovery, enabling the identification of molec-
ular drug targets in a significant number of human diseases.
This molecular view of diseases has contributed to the impor-
tance of combining primary sequence data with three-dimen-
sional structure and has increased the awareness of computa-
tional homology modeling and its potential to elucidate
protein function. In particular, when important proteins or
novel therapeutic targets are identified—like the family of pro-
tein tyrosine phosphatases (PTPs) (reviewed in reference
53)—a structure-function classification of such protein families
becomes an invaluable framework for further advances in bio-
medical science. Here, we present a comparative analysis of
the structural relationships among vertebrate PTP domains
and provide a comprehensive resource for sequence analysis of
phosphotyrosine-specific PTPs.
PTPs are a key group of signal transduction enzymes which,
together with protein tyrosine kinases, control the levels of
cellular protein tyrosine phosphorylation. Protein tyrosine ki-
nases phosphorylate cellular substrates on tyrosine residues,
and much progress has been made over the last 20 years in
elucidating their significance in signal transduction (for re-
views, see references 26, 30, 31, 33, 71, and 72). However, it is
only recently that the complexities of the PTPs have been
appreciated. Thus, today it is recognized that the capacity of
PTPs to dephosphorylate phosphotyrosine residues selectively
on their substrates plays a pivotal role in initiating, sustaining
and terminating cellular signaling (for reviews, see references
1, 4, 19, 32, 35, 46, 55, and 83). It has been shown that both the
catalytic domain and noncatalytic segments of the PTPs con-
tribute to the definition of substrate specificity in vivo.
Whereas noncatalytic domains may target the PTPs to specific
intracellular compartments in which the effective local concen-
tration of substrate is high (3, 19, 51), the PTP catalytic do-
mains themselves confer site-selective protein dephosphoryla-
tion by recognizing both the phosphotyrosine residue to be
dephosphorylated and its flanking amino acids in the substrate.
The combination of structural studies, kinetic analysis of PTP
domains (37, 74, 76, 90, 91, 96), and studies involving substrate-
trapping mutants (20, 23, 89) as well as PTP chimeras (60, 82)
has convincingly demonstrated that isolated PTP domains may
exhibit exquisite substrate selectivity.
The structurally conserved PTP domain defines membership
of the PTP family, and three groups of enzymes are capable of
dephosphorylating tyrosine-phosphorylated residues (57): (i)
classical PTPs, (ii) dual-specificity PTPs, and (iii) low-molecu-
lar-weight PTPs. The dual-specificity PTPs and low-molecular-
weight PTPs will not be considered further but have been
reviewed (43, 70). The classical PTPs, which are the focus of
the present study, encompass both transmembrane receptor-
like and nontransmembrane enzymes, and the wide spectrum
of protein domains present within this family highlight their
diverse cellular functions. Most transmembrane receptor-like
PTPs (RPTPs) contain two cytoplasmic PTP domains, a mem-
brane proximal domain (D1) and a membrane distal domain
(D2), and in addition have a single transmembrane segment
and an extracellular domain.
As the study of PTPs has developed, the availability of an
impressive number of X-ray crystal structures (for an updated
list, see reference 53) and phylogenetically divergent cDNAs
has permitted a detailed structural analysis of the evolutionary
relationships among vertebrate PTP domains. Together with
numerous enzymological studies revealing insights into the
mechanism of PTP catalysis (12, 14, 25, 34, 47, 68, 77, 80,
97–99, 101), this development has permitted us to combine an
extensive set of amino acid sequences with representative
three-dimensional protein structures to derive new and refined
information regarding PTP structure, substrate recognition,
and evolutionary conservation. Because perturbed levels of
tyrosine phosphorylation are associated with diseases such as
cancer, autoimmunity, and allergy, we hope that this compre-
hensive analysis of the PTP family may assist in providing the
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structural basis for novel therapeutic strategies involving the
development of selective PTP inhibitors.
In the present study, we have compiled a total of 319 verte-
brate PTP sequences, including splice variants and partially
overlapping sequences. Subsequent analysis narrowed these
319 GenBank entries down to 113 distinct PTP catalytic do-
main sequences (including non-transmembrane PTPs and do-
mains D1 of RPTPs) and 38 domain D2 sequences from hu-
man and other vertebrate species. From this collection of 151
PTP domain sequences, we identified 37 distinct human PTP
genes, which we aligned to assist in the identification of con-
served regions. This sequence comparison allowed the classi-
fication of the vertebrate PTP family into 17 principal subtypes.
The motifs identified from our amino acid sequence alignment
are reviewed in terms of their location in the tertiary structure
and, where relevant, their catalytic function. As a low-resolu-
tion and automated homology modeling approach, we applied
the methodology of C-regiovariation score analysis (10, 11) to
identify foci within the PTP domain tertiary structure, where
amino acid conservation extended in three dimensions. The
conserved foci identified by this approach are discussed includ-
ing a previously unrecognized conserved cluster of residues
located on the face of the molecule opposite the active site.
Collection of unique vertebrate PTP domains. Following the
identification of the first PTP in 1988 (84), intense efforts in the
application of PCR and low-stringency screening led to the
rapid discovery of a wide variety of other PTP family members.
As often happens in rapidly developing research fields, several
identical PTPs were independently cloned by different research
groups and hence given different names and accession num-
bers. Consequently, the first step in our structural study was to
compile a database of unique PTP domains. A BLAST search
(2) of the National Center for Biotechnology Information
(NCBI) GenBank database was performed using nucleotide
sequences encoding several divergent PTP catalytic domains
(PTP1B, SHP1, MEG2, PEST, PTPH1, PTPD1, CD45, RPTP,
LAR, RPTP, RPTP, RPTP, STEP, and the PTP-like pro-
tein IA2). This sequence similarity search generated over 3,500
database hits that, following the exclusion of expressed se-
quence tags and sequences encoding dual specificity and low-
molecular-weight phosphatases, identified 319 vertebrate PTP
entries. Alignment of the 5 untranslated regions and the
amino acid sequences of these 319 entries revealed a large
number of different splice variants, partially overlapping se-
quences, and duplicate database entries. In total, 113 distinct
PTP catalytic domains and 38 domain D2 sequences from
tandem domain RPTPs were uncovered. This collection of
PTP domains contains 37 human PTP genes and ortholog
sequences from vertebrate species (Table 1). Our compilation
of PTP-related sequences illustrates the redundancies often
observed among GenBank database entries. Moreover, since
many of the deposited sequences lack structural or functional
annotation, there is a strong requirement for grouping these
entries in order to gain access to the combined body of bio-
chemical, structural, and/or functional information known for
any given PTP. To this end, we have grouped the entries in
Table 1 based on PTP domain sequence similarity (by subtype)
and have identified the most likely human orthologs. In addi-
tion, to facilitate access to MEDLINE literature for any given
PTP of interest, an electronic version of Table 1 can be re-
trieved (http://science.novonordisk.com/ptp), in which the ac-
cession numbers are hyperlinked to the NCBI website and
PubMed literature database (http://www.ncbi.nlm.nih.gov).
We have also mapped the chromosomal locations of the 37
human PTPs described in this study, allowing a detailed de-
scription of their intron and exon structure. Genomic clones,
EMBL accession numbers, and the position of these PTPs in
the human genome are summarized in Table 2. In addition, we
acknowledge that the draft of the human genome contains
additional sequences that conform to the PTP consensus mo-
tifs, but the expression of these hypothetical proteins has not
yet been verified. Only transcripts that have been confirmed
from in vitro or in vivo studies are considered in the present
structure-function analysis of PTP domains.
Primary sequence alignment of PTP domains. To provide a
platform for classification of members of the PTP family and
for the identification of conserved residues, a multiple-se-
quence alignment was constructed using the entire set of ver-
tebrate PTPs identified above (Table 1). In Fig. 1, we have
reduced the alignment to a sequence comparison between the
37 human PTP domains, but the extended version used in our
analysis can be retrieved from the World Wide Web (http:
//science.novonordisk.com/ptp) and includes all 113 vertebrate
PTP catalytic domains. To enable the assessment of both the
level of conservation and the degree of sequence variation, the
alignment is color coded according to amino acid identity (see
legend to Fig. 1). The N- and C-terminal boundaries for this
alignment correspond to residues 1 to 279 in PTP1B and en-
compass all invariant residues and structurally conserved ele-
ments. In the past, the PTP domain has been described to
consist of 250 amino acids, but the extensive set of PTPs
included in this multiple-sequence alignment, combined with
structural knowledge and secondary-structure prediction algo-
rithms, has permitted us to identify conservation at the N
terminus of the PTP domain comprising the 1 and 2 heli-
ces of PTP1B (37) (Fig. 1). We now define the PTP domain as
comprising 280 residues. In Fig. 1, an alignment of domain
D2 of RPTPs is included, but these domains were not used in
the definition of the PTP consensus sequence.
PTP family can be classified into 17 subtypes. Since phylo-
genetic analysis of sequence alignments serves as a useful tool
for the classification of homologous proteins, we derived a
phylogenetic tree from our alignment of 113 PTP catalytic
domains (Fig. 2). The clustering of sequences into divergent
branches of this tree provided a basis for subdivision of PTP
family members (see figure legend for details). In total, 17
principal PTP subtypes were identified as indicated in Fig. 2. In
addition, all PTP domain D1 sequences from tandem domain
RPTPs clustered into one major trunk of the phylogenetic tree,
allowing the definition of a PTP supertype encompassing these
five RPTP subtypes (R1/R6, R2A, R2B, R4, and R5). The high
intrasubtype sequence identity of 60 to 80% among domain D1
of these RPTPs, compared to 45 to 60% among PTP domains
of the RPTP-like subtype (R3), which contain only one PTP
domain, supports earlier suggestions that during evolution,
intragenic catalytic domain duplication (i.e., duplication of the
PTP domain within an ancestral PTP gene) preceded gene
duplication (88). Consistent with this concept, all domain D2
sequences also clustered into one separate branch of the phy-
logenetic tree (data available at http://science.novonordisk














TABLE 1. Compilation of nonredundant set of 113 vertebrate PTPsa
Name Subtype Humanortholog Full-length name Synonym(s) Swiss-Prot GenBank accession no.
Non-RPTP
subtypes
hPTP1B NT1 PTP1B PTP-1, PTP-1B P18031 M31724, M33689,
mPTP1B NT1 PTP1B PTP1B PTP-1, HA2, PTP-HA2 P35821 U24700, Z23057, M97590, L40595
rPTP1B NT1 PTP1B PTP1B PTP-1 P20417 M33962
cPTP1B NT1 PTP1B PTP1B O13016 U86410
zPTP1B NT1 PTP1B PTP1B AF097481, AF097482, AF097483
hTCPTP NT1 TC-PTP (T-cell
phosphatase)
PTP-2 P17706 M25393, M81478, M80737
mTCPTP NT1 TCPTP TC-PTP (T-cell
phosphatase)
PTP-2 O06180 S52655, M81477, M80739
rTCPTP NT1 TCPTP TC-PTP (T-cell
phosphatase)
PTP-2, PTP-S P35233 X58828




P29350 M74903, X62055, M77273, M90388,
X82817, X82818
mSHP1 NT2 SHP1 Src homology domain
2-containing PTP1
P29351 M68902, M90389, U65953, U65954,
U65955
rSHP1 NT2 SHP1 Src homology domain
2-containing PTP1
U77038




O06124 D13540, L03535, L07527, X70766,
L08807, S78088, S39383
mSHP2 NT2 SHP2 Src homology domain
2-containing PTP2
SH-PTP2, Syp P35235 L08663, D84372
rSHP2 NT2 SHP2 Src homology domain
2-containing PTP2
PTP-1D P41499 U09307, U05963, D83016
cSHP2 NT2 SHP2 Src homology domain
2-containing PTP2
SH-PTP2, Syp U38620
xSHP2 NT2 SHP2 Src homology domain
2-containing PTP2
U15287
hMEG2 NT3 Megakaryocyte-PTP2 P43378 M83738
mMEG2 NT3 MEG2 Megakaryocyte-PTP2 AF013490
xPTPX1 NT3 —b L33098
xPTPX10 NT3 — L33099
hPEST NT4 Pro, Glu, Ser, Thr-
rich PTP
PTP-PEST, PTPG1 O05209 D13380, M93425, S69184
mPEST NT4 PEST Pro, Glu, Ser, Thr-
rich PTP
PTPP19 P35831 X86781, X63440, S36169
rRKPTP NT4 PEST Rat kidney PTP D38072
hLyPTP NT4 Lymphoid phospha-
tase
LyP1, LyP2 AF001846, AF001847, AF077031,
AF150732
mPEP NT4 LyPTP Hematopoietic cell
PTP
P29352 M90388
hBDP1 NT4 Brain-derived phos-
phatase 1
X79568
rPTP20 NT4 BDP1 U69673
mPTPK1 NT4 BDP1 PTPFLP1 (fetal liver
phosphatase 1)
U35124, U52523, U49853
hMEG1 NT5 Megakaryocyte-PTP1 PTPG1, PTPF36-15 P29074 M68941, AAB26477
mPTPtep NT5 MEG1 Testis-enriched phos-
phatase
PTPMEG AF106702
zPTPH1 NT5 MEG1 AF097477, AF097478, AF097479,
AF097480
hPTPH1 NT5 PTPH1 P26045 M64572, S39392
mPTPRL10 NT6 PTPD1 Q62136 D37801, D83072
rPTP2E NT6 PTPD1 PTPD1 Q62728 U17971, U18293
hPTPD1 NT6 PTPD1 PTPD1 Q16825 X79510
hPTPD2 NT6 PTPD2 PEZ (phosphatase ezrin-
like)
Q15678 X82676
mPTP36 NT6 PTPD2 PTPD2 Q62130 D31842
hPTPBAS NT7 FAS-associated PTP1 BAS, PTP1E, PTPE1,
FAP-1, PTPL1, CD95
Q12923 X80289, U12128, D21209, D21210,
D21211, U81561, X79676
mPTPBL NT7 PTPBAS DPZPTP, PTPRIP D28529, Z32740, D83966
bPTPBA14 NT7 PTPBAS U20807
hPTPTyp NT8 Testis-specific tyro-
sine phosphatase
Typ AL050040
mPTPTyp NT8 PTPTyp Testis-specific tyro-
sine phosphatase
Typ D64141
Continued on following page















Name Subtype Humanortholog Full-length name Synonym(s) Swiss-Prot GenBank accession no.
hHDPTP NT9 His domain-containing
PTP
HD-PTP, PTPTD14 T14756, AB025194, AB040904,
AL110210, AF169350
rPTPTD14 NT9 HDPTP AF077000
RPTP subtypes





mCD45 R1/R6 CD45 Cluster of differentia-
tion 45
LCA, T200, Ly5 P06800 M14342, M92933, M33482
rCD45 R1/R6 CD45 Cluster of differentia-
tion 45
Leukocyte common antigen P04157 M10072, Y00065, M25820, M25821,
M25822, M25823, K03039
cPTPlambda R1/R6 CD45 PTPlambda L13285, Z21960
xCD45 R1/R6 CD45 Cluster of differentia-
tion 45
AF024438
hPTPlambda R2A RPTPlambda PCP2, PTPomicron, PTPfmi,
PTPpi, PTPi, PTPRO
Q92729 U60289, X97198, U73727, U71075,
X95712,AL049570
mPTPlambda R2A PTP RPTPlambda PTPftp1, PTPpsi U55057, D88187
rPTPpsi R2A PTPI RPTPpsi U66566
hPTPkappa R2A RPTPkappa Q15262 L77886, Z70660
mPTPkappa R2A PTP	 RPTPkappa P35822 L10106
hPTPmu R2A RPTPmu P28827 X58288
mPTPmu R2A PTPm RPTPmu P28828 X58287
hPTPrho R2A RPTPrho AF043644, AL024473, AL022239,
Z93942
mPTPrho R2A PTPr RPTPrho AF152556
xPTPrho R2A PTPr RPTPrho AF173857
hLAR R2B LCA-related PTPc PTP-LAR P10586 Y00815
mLAR R2B LAR LCA-related PTP PTP-LAR Z37988
rLAR R2B LAR LCA-related PTP PTP-LAR L11586, U00477, X83546, X83505
xLAR R2B LAR LCA-related PTP PTP-LAR AF197945







hPTPsigma R2B RPTPsigma U35234, U40317, U41725,
AC005788, S78080, S78086
rPTPsigma R2B PTP RPTPsigma LAR-PTP2, PTP-PS, PTP-P1 L11587, AF073999
mPTPNU3 R2B PTP PTPsigma, PTPT9a, PTPT9b X82288, D28530, D28531
xCRYPalpha R2B PTP AF198450
hPTPS31 R3 I32038, I32036, I32037, I32035,
I32039
rPTPGMC R3 PTPS31 Glomerular mesangial
cell receptor
PTPRQ, PTPGMC1 AF063249
hGLEPP1 R3 Glomerular epithelial
protein 1
PTPU2, PTProt U20489, Z48541
mPTPphi R3 GLEPP1 PTP-BK, PTP-ro, mGLEPP1 U37465, U37466, U37467,
AF295638
rPTPBEM1 R3 GLEPP1 Brain-enriched mem-
brane-associated PTP1
PTPD30, BSM-1 D45412, U28938
rabPTPoc R3 GLEPP1 Osteoclastic PTP U32587
cPTPcryp2 R3 GLEPP1 CRYP-2 U65891
hPTPbeta R3 RPTP P23467 X54131
mPTPbeta R3 PTP Vascular endothelial PTP
(VE-PTP)
X58289, AF157628
hDEP1 R3 Density-enhanced PTP PTPeta, CD148, F-36-12 Q12913 U10886, D37781, AAB26475
mPTPBYP R3 DEP1 RPTPbeta-like PTP PTPeta Q64455 D45212
rDEP1 R3 DEP1 Density enhanced PTP Vascular PTP-1 U40790
hSAP1 R3 Stomach cancer-associ-
ated PTP
hPTPH D15049, AAF91411
rPTPBEM2 R3 SAP1 Brain-enriched mem-
brane-associated PTP2
D45413
mPTPesp R3 — Embryonic stern cell PTP OST-PTP P70289 U36488, AF300701
rOSTPTP R3 — Osteotesticular PTP O64612 L36884
hPTPalpha R4 RPTPalpha P18433 M34668, X54130, X54890, X53364
mPTPalpha R4 PTP RPTPalpha LCA-related PTP P18052 M36033, M33671, M36034
rPTPalpha R4 PTP RPTPalpha Q03348 L01702
cPTPalpha R4 PTP RPTPalpha Z32749, L22437,
xPTPalpha R4 PTP RPTPalpha U09135
hPTPepsilon R4 RPTPepsilon P23469 X54134
mPTPepsilon R4 PTPε RPTPepsilon P49446 U35368, U36758, D83484, U62387,
U40280
rPTPepsilon R4 PTPε RPTPepsilon D78610, D78613
Continued on following page














.com/ptp), suggesting structural, and perhaps functional, con-
servation among these PTP domains. The result of the present
classification system, together with a diagram of the overall
domain structure of a representative member of each PTP
subtype, is presented in Fig. 3.
Sequence similarity between PTP domains can be used for
overall structural classification of PTP family. A major finding
from the phylogenetic analysis of the alignment is the very
close relationship between PTP domain sequence similarity
and the presence of similar structural and functional domains
in the full-length proteins (Fig. 3). Thus, the RPTPs, previously
classified by their extracellular domains into nine distinct sub-
types (8), are categorized into virtually identical groups based
solely on catalytic domain sequence homology (hence the use
of the existing nomenclature for the RPTPs) (8). However, one
difference lies with chicken PTP. Based on its unique extra-
cellular segment, this PTP was previously assigned to its own
subtype (R6). but the present classification system suggests
that it is the avian homologue of CD45. Therefore, we have
included it within the CD45 subtype and defined it as R1/R6.
For the nontransmembrane PTPs, the nine subtypes defined
from the phylogenetic analysis of PTP domains also correlated
with the presence of particular regulatory and/or targeting
domains. Thus, the SH2 domain-containing PTPs, SHP1 and
SHP2, are classified as one PTP subtype (NT2), and the three
PTPs containing a carboxy-terminal PEST-like domain (viz.
human BDP, PEST, and LyPTP) are categorized as another
distinct subtype (NT4) (Fig. 2). However, it should be noted
that the FERM domain-containing PTPs, which vary in their
central segments and contain distinct numbers of PDZ do-
mains, fall into three distinct subtypes (NT5, NT6, and NT7).
Although HDPTP (85) and PTPTyp (58) contain segments
with a high content of proline, glutamate, serine, and threonine
residues (PEST-like domains), they are categorized as distinct
subtypes (NT8 and NT9). Since PEST-like sequence annota-
tion is subjective and these sequences do not correspond to
conserved protein domains in the Pfam and Interpro databases
(5), the functions of these PEST-like segments are most likely
unrelated.
Another important observation from the phylogenetic map-
TABLE 1—Continued
Name Subtype Humanortholog Full-length name Synonym(s) Swiss-Prot GenBank accession no.
hPTPgamma R5 RPTPgamma P23470 L09247, X54132
mPTPgamma R5 PTP RPTPgamma Q05909 L09562
cPTPgamma R5 PTP RPTPgamma Q98936 U38349
cPTPzeta R5 RPTPzeta L27625
hPTPzeta R5 PTP RPTPzeta P23471 M93426, X54135, U88967
rPTPzeta R5 PTP RPTPzeta Q62656 U09357
hPCPTP1 R7 PC12-derived PTP PTPch1g, PTPCOM1,
hCh1PTP, PTPEC
D64053, U77916, U77917, U42361,
X82635, Z79693
rPCPTP1 R7 PCPTP PC 12-derived PTP PC12-PTP1, CBPTP D38292, D64050, U14914






mSTEP61 R7 STEP Striatum-enriched
phosphatase
P54830 U28217, S80329, U28216
rSTEP R7 STEP Striatum-enriched
phosphatase
P35234 S49400
hHePTP R7 Hematopoetic PTP Leucocyte PTP P35236 M64322, D11327
rLCPTP R7 HePTP Leukocyte PTP Hematopoetic PTP P49445 U28356
IRL subtyped
hPTPIA2 R8 Islet cell antigen Islet cell antigen, ICA-
512
Q16849 L18983, Z48226, X62899
mPTPIA2 R8 IA2 Islet cell antigen PTP35 Q60673 U11812, X74438
rPTPIA2 R8 IA2 Islet cell antigen BEM-3, PTPN, ICA105,
PTPLP
Q63259 D45414, X92563, D38222, U40652
bPTPIA2 R8 IA2 Islet cell antigen ICA512 P56722 AF075170
hPTPIA2beta R8 PTP-IA-2beta IAR, RPTPX Q92932 U65065, AF007555, L76258,
U81561, AB002385





macPTPIA2beta R8 IA2 IA2beta O02695 U91574
rPTPNE6 R8 IA2 IA2beta, phogrin Q63475 U73458, Z50735
a Summary of vertebrate PTP database entries showing nomenclature and accession numbers assigned to each PTP. The PTP name is that most frequently used in
the PubMed literature database. The letters preceding the PTP name represent the following: b, bovine; c, chicken; h, human; m, mouse; mac, monkey; r, rat; rab, rabbit;
x, xenopus; z, zebra fish. Entries (either Swiss-Prot or GenBank) were used for the primary amino acid sequence alignment of PTP domains (Fig. 1). The PTP entries
are grouped according to catalytic domain sequence similarity and have been classified into 17 PTP subtypes: nine nontransmembrane (NT1 to NT9) and eight receptor
types (R1/R6, R2a, R2b, R3, R4, R5, R7, and R8). The basis for this classification is detailed in the legend to the homology tree in Fig. 2. The existing nomenclature
for RPTP subtypes was used since these have previously been classified into almost identical groups based on extracellular domain similarity (8). Ortholog pairs of
proteins were identified from the phylogentic analysis (Fig. 2). Note that RPTP subtypes R3, R4, and R7 include both transmembrane and cytoplasmic enzymes (see
text for details). An electronic version of this table can be retrieved (http://science.novonordisk.com/ptp), in which the accession numbers are hyperlinked to the NCBI
website and PubMed literature database (http://www.ncbi.nim.nih.gov).
b —, no obvious human ortholog identified.
c LCA, leukocyte common antigen.
d IRL, IA2 receptor-like.














ping of PTP domains relates to the traditional classification of
this protein family into two broad classes: transmembrane
RPTPs and intracellular nontransmembrane PTPs. Although
we have maintained this conceptual subdivision for the classi-
fications shown in Fig. 2 and 3, it is significant that several of
the PTP subtypes (R3, R4, and R7) contain both transmem-
brane and nontransmembrane enzymes. Thus, the PCPTP1-
like subtype (R7) contains both the receptor-like enzyme
PCPTP1 (mouse PTP-SL) and two cytoplasmic enzymes STEP
and HePTP (mouse LCPTP), for which no transmembrane
isoforms have been identified so far. For the RPTP subtype
R3, alternative splicing of GLEPP1 mRNA (mouse PTP)
generates either a cytoplasmic or transmembrane form of the
enzyme (67), and for PTPε (subtype R4), the alternate usage of
isoform specific 5 exons and promoters generates either a
cytoplasmic or transmembrane form of the enzyme (18). Since
the above examples illustrate that the classical subdivision of
PTP family members, based on the presence or absence of an
extracellular and transmembrane segment may be ambiguous,
a novel classification system based on catalytic domain se-
quence similarity, as described here, was considered appropri-
ate. We have made the phylogenetic tree available (http://science
.novonordisk.com/ptp), and we hope it will serve as a useful
tool for the classification of novel PTPs discovered in the
postgenomic area.
Ten conserved motifs define family of PTPs. Another appli-
cation of the present PTP sequence alignment is the identifi-
cation of conserved motifs that define this class of signal-
transducing enzymes. In particular, the definition of consensus
amino acid sequences—either for the PTP family as a whole or
for functional and therapeutically interesting PTP subtypes—
will help to probe genomes of other organisms for the presence
of PTP orthologs and thereby identify relevant model organ-
isms for rapid genetic analysis of the involvement of PTPs in
control of fundamental cellular functions.
In the present study, we have defined a conserved motif as a
stretch of three or more amino acids in which two of three of
the residues are at least 80% conserved by amino acid similar-
ity (substitution groups are specified in Table 3). Based on
amino acid identity, 10 discrete and highly conserved motifs
(M1 to M10) were identified from the alignment of PTP do-
mains (Table 3). In addition, outside these motifs, seven single
TABLE 2. Chromosomal locations of human PTP genes and their genomic clonesa
Protein name Chr Band Ensembl gene ID Genomic clones (EMBL accession no.)
hLyPTP 1 p13.1 ENSG00000081021 AL365321, AL137856
hLAR 1 p34.2 —c AL158083
hPTPlambda 1 p35.2 ENSG00000060656 AL049570
hCD45 1 q32.1 ENSG00000081237 AL355988
hHePTP 1 q32.1b — —
hPTPD2 1 q41 ENSG00000065995 AC026065, AC068586
hMEG1 2 q14.2 — AC016691
hBDP1 2 q21.2 ENSG00000072135 AC068137
hPTPIA2 2 q35 — AC60820
hPTPgamma 3 p14.2 — AC024885
pHDPTP 3 p25.1 — AC023230
hPTPBAS 4 q22.1 — AC007525, AC079237
hPTPkappa 6 q22.33 — AL035465
hPEST 7 q11.23 ENSG00000127947 AC006451, AC090421
hPTPzeta 7 q31.33 ENSG00000106278 AC073471, AC006020
hPTPIA2beta 7 q36.3 ENSG00000002748 AC005481, AC006372, AC006321
hPTPdelta 9 p23 ENSG00000099228 AC026466
hPTPH1 9 q32 — AL359963, AL450025, AC013568
hPTPTyp 10 q11.22 ENSG00000126542 AL358791
hPTPepsilon 10 q26.2 ENSG00000132334 AL390236
hDEP1 11 p11.2 — AC026975
hSTEP 11 p15.1 ENSG0000110786 AC016750
hGLEPP1 12 p12.3 ENSG00000084474 AC007542
hSHP1 12 p13.31 ENSG00000111679 AC006512, U47924, M86525, U72506
hPCPTP1 12 q15 ENSG00000111585 AC055123, AC083809, AC015544, AC090676, AC090670
hPTPbeta 12 q15 — AC015544, AC083809, AC011053, AC025569
hPTPS31 12 q21.31 ENSG00000091041 AC078825, AC074031
hSHP2 12 q24.13 ENSG00000089131 AC004086, AC004216
hPTPD1 14 q31.3 — AL353786, AL162171, AL049834
hMEG2 15 q23 — AC009712
hTCPTP 18 p11.21 ENSG00000128772 AP001077, AC007734, AP002449
hPTPmu 18 p11.22 ENSG00000069927 AC006566, AC021310, AP001094, AC069097, AC023663
hPTPsigma 19 p13.3 ENSG00000105426 AC005338, AC005788
hSAP1 19 q13.42 ENSG00000080031 AC010327, AC010619
hPTPalpha 20 p13 ENSG00000037980 AL121905, AL138803
hPTPrho 20 q12 ENSG00000087530 AL024473
hPTP1B 20 q13.13 ENSG00000063920 AL133230, AL034429
a The PTP amino acid sequences of the proteins were searched against those in the human genome databases (www.genome.ucsc.edu and www.ensembl.org) in order
to determine their chromosomal locations (chromosome number [Chr] and band). Genomic clones for the human PTP genes (annotated genes in Ensembl and EMBL
accession numbers) are hyperlinked to their respective databases (see http://science.novonordisk.com/ptp for the electronic version of the table).
b No genomic clones were found. Chromosomal localization was determined by fluorescent in situ hybridization (93).
c —, no gene annotation in Ensembl has been available so far.














conserved residues were found (Glu19, Glu115, Arg156,
Arg169, Leu192, Arg254, and Arg257; residues are numbered
according to the numbering of human PTP1B) (Table 4). Sev-
eral of the conserved residues identified have previously been
reviewed (6, 95), and their functions have been studied exten-
sively by site-directed mutagenesis (20, 78) and X-ray crystal-
lography (13, 95). However, the existing PTP consensus se-
quences in the literature have been defined from a much
smaller number of aligned sequences, and some important
structural (noncatalytic) motifs have received less attention or,
until now, have remained undisclosed (Table 3). Therefore, an
overview of all motifs and their proposed function together
with an evaluation of their degree of conservation in three-
dimensional space is provided below.
Superimposition of PTP domains reveals conserved C-
backbone trace that allows evaluation of the multiple sequence
alignment in 3D space. To date, X-ray crystallographic struc-
tures are available for seven different PTP catalytic domains,
including the nontransmembrane enzymes (PTP1B, Yop51,
SHP1, and SHP2) (7, 27, 79, 92) and RPTP domains (PTP,
PTP, and LAR) (29, 50, 56). When the crystal structures of
vertebrate PTP domains were superimposed, we observed a
conserved fold and a consistent C-backbone trace (Fig. 4).
This striking conservation of tertiary structure allowed us to
quantify the degree of conservation of each amino acid residue
in three dimensional space (i.e., relative to the conservation of
neighboring residues). In brief, such low-resolution homology
modeling, the so-called C-regiovariation score analysis (10,
11), uses the information in a set of aligned sequences and
calculates the average degree of conservation which has oc-
curred within a given “sphere of influence” for each residue
position along the folded polypeptide backbone of a represen-
tative tertiary structure. The method has previously identified
interactive sites for cytochrome c, the pancreatic trypsin inhib-
itor family of proteinases, and carboxypeptidases A and B (10,
11). To avoid bias towards catalytic domains that are repre-
sented by a large number of ortholog sequences, we selected a
nonredundant set of 37 aligned human PTP catalytic domains
(Fig. 1). In agreement with C-regiovariation score analyses of
other protein families (10, 11), we observed that a 6- to 8-A˚
sphere of influence provides an optimal signal-to-noise ratio
and yields consistent results for different PTP templates (not
shown). All figures in the present work were produced with a
sphere of influence of 7 A˚.
Structural motifs make up the most highly conserved re-
gions in PTP structure. The score values for the C-regiovaria-
tion analysis are shown in Fig. 5. Conserved residues in con-
served surroundings are identified as peaks. Hydrophobic
segments in the primary amino acid sequence alignment make
up the most highly conserved microenvironments in the PTP
structure. Thus, the structural motifs TXXDFWXMXW (M5),
IVMXT, (M6) and KCXXYWP (M7) (Table 3) together form
a densely packed hydrophobic core with energetically favored
T stacking (52) of their aromatic ring systems (Phe95, Trp96,
Tyr124, and Trp125). Extensive hydrophobic interactions were
also observed between the stretch of amino acids DYINAS
(M3) and [F/Y]IAXQGP (M4), which packed together in the
PTP crystal structure by arrangement in parallel and anti-
parallel -sheets (Fig. 6). Hydrophobic packing is important
for protein structures to gain stability (16). In agreement with
this concept, thermosensitive variants of LAR, TC-PTP, and
PTP1B (54, 86) were found to contain mutations in the hydro-
phobic motifs above (M2 to M7), indicating a critical role of
these residues in stabilizing the secondary structure of the PTP
domain. Moreover, projection of the secondary structure of
PTP1B onto the alignment (Fig. 1) and C-regiovariation
score values (Fig. 5) revealed that the -sheets and -helixes in
the structural motifs M2 to M6 are dominated by conservative
amino acid substitutions, whereas nonconservation mutations
frequently have been accepted in the regions flanking these
secondary structures. To visualize the conservation of the core
of the PTP structure, conserved residues are indicated on the
C-backbone (Fig. 6).
We found that the functional motif defined by the PTP
signature sequence, VHCSXGXGR[T/S]G (M9), together
with the structural motif [F/Y]IAxQGP (M4), constitutes the
most highly conserved area within the PTP tertiary structure
(Fig. 5). Importantly, the C-terminal stretch of residues QGP
in motif M4 leads to the termination of a -sheet and is in-
volved in a bend situated very near to the catalytic cysteine
(Cys215) (Fig. 6). Intriguingly, the conserved proline in the
[F/Y]IAXQGP motif (Pro87 in PTP1B) is replaced by a cys-
teine in SHP1 and SHP2, which is likely to result in a more
flexible main chain with a greater configurational entropy (27,
92). Whereas the structural motifs are detailed in Table 3, we
will discuss further the role of conserved residues in the four
motifs (M1 and M8 to M10) that define the catalytic function-
ality of PTP domains.
PTP signature motif or phosphate-binding loop (motif 9).
The active site sequence VHCSXGXGR[T/S]G (residues 213
to 223 in PTP1B) defines the PTP family and is often referred
to as the PTP signature motif or the “PTP loop.” Residues in
this motif (M9) form the phosphate-binding loop, which is
located at the base of the active site cleft. The cysteine in the
PTP signature motif acts as a nucleophile and accepts phos-
phate transiently during catalysis (25), and the invariant
Arg221 is involved in both substrate binding and in the stabi-
lization of the phosphoenzyme intermediate (99). Our C-
regiovariation score analysis identified two conserved polar
residues (Glu115 and Arg257) in a microenvironment of the
PTP structure which otherwise has accommodated many
amino acid substitutions during evolution (Fig. 5). Importantly,
these two residues form hydrogen bonds with the PTP loop,
with the invariant Glu115 determining the position of Arg221
through a conserved salt bridge between the carboxy and gua-
nidinium groups. Their invariance among human PTPs high-
lights their principal role in defining the architecture and func-
tion of the phosphate-binding loop. The close proximity of the
catalytic Cys215 residue to main-chain amide groups of the
PTP loop and hydrogen bonding with both the side chain of
Arg221 and the hydroxyl group of Ser222 stabilizes the thiolate
(deprotonated) form of the cysteine, favoring its function as a
nucleophile (7, 94, 97). Moreover, theoretical investigations
revealed that Arg257 may also contribute to stabilizing the
nucleophilic nature of the active site cysteine (65). Mutation of
the catalytic Cys215 to serine or alanine abrogates all enzyme
activity while maintaining affinity for substrates in vitro, a fea-
ture that has been successfully utilized to obtain structures of
PTPs in complex with phosphotyrosine peptide substrates (37,
74, 75, 91).














Phosphotyrosine recognition loop (motif 1). Whereas the
phosphate group in the substrate phosphotyrosine residue is
surrounded by residues corresponding to the PTP signature
motif (37, 99), aromatic (Tyr46 and Phe182) and nonpolar
(Val49, Ala217, and lle219) amino acids pack with the phenyl
ring of the phosphotyrosine and delineate the boundaries of
the active site binding pocket (37). The fact that these five
residues are conserved by amino acid similarity suggests that
the mechanism for recognition of the phosphotyrosine moiety
of the substrate is similar among all tyrosine-specific PTPs.
Collectively, the residues KNRY (Lys43 to Tyr46) are known
as the phosphotyrosine recognition loop (37) since this ele-
ment (M1) defines the depth of the active site crevice and
hence creates selectivity for phosphotyrosine by excluding the
hydrolysis of the shorter phosphoserine or phosphothreonine
residues in target proteins (37, 91).
WPD loop (motif 8). The binding of phosphopeptides to the
PTP loop promotes a major conformational change in the
catalytic site surface loop (residues 179 to 187) that moves
several angstroms to close the active site pocket and trap the
bound phosphotyrosine (37, 80). The amino acid sequence of
this surface loop is quite diverse, except for the WPDXGXP
motif that contains a general acid-base catalyst (Asp181) (98).
The presence of two proline residues (which do not support
hydrogen bonding) and a glycine in the hinge bend region of
this segment is critical for the dynamics of the WPD loop
motion (63, 64). Comparison of the structures of ligand-free
form of the Yersinia PTP (Yop51) and the enzyme complexed
FIG. 1. Sequence comparison of human PTP domains. Shown is an amino acid sequence alignment of 37 human PTP domains (from
nontransmembrane PTP and RPTP domains D1) (above) and comparison with domain D2 sequences of RPTPs (below). Amino acids are
numbered according to the residue position in human PTP1B. The locations of -helices and -strands (based on the X-ray crystal structure of
PTP1B [7]) are shown at the top of the alignment. Twenty-two invariant residues (underscored) and 42 highly conserved residues (80% identity)
are indicated at the bottom of the alignment. The PTP consensus motifs (M1 to M10) are detailed in Table 2. Amino acids are color coded
according to their degree of conservation, as indicated below the alignment. Nonconserved residues involved in the definition of substrate
selectivity-determining regions are boxed with black lines (see text and Fig. 9). The four-residue conserved linker in tandem RPTP enzymes is
boxed in yellow (above) and corresponds to encircled area 1 in Fig. 8. Sequences were aligned using the Clustalw algorithm and the Genetics
Computer Group PileUp software (version 8.1) by applying the BLOSUM 62 scoring matrix together with default gap creation and extension
penalty. Alignment of the N termini of the PTP domains was guided by crystallographic structural data and secondary structure predictions
(nnpredict at http://www.cmpharm.ucsf.edu). The complete alignment of all vertebrate PTP domains can be retrieved (http://science.novonordisk
.com/ptp) in several standard GCG formats, including MSF, TFA, and ALN.














with oxyanions (77, 80) has revealed that an interaction be-
tween the invariant tryptophan in the WPD loop (Trp354,
equivalent to Trp179 in PTP1B) and the above-mentioned
arginine in the PTP loop (Arg409, equivalent to Arg221 in
PTP1B) plays an important role in closure of the WPD loop.
Enzyme kinetic analyses of this PTP has confirmed that muta-
tion of the hinge Trp179 disables catalysis (28, 42). Closure of
the WPD loop is critical for phosphoester hydrolysis, since it
positions Asp181 close to the scissile oxygen of the tyrosyl
substrate, allowing it to donate a proton to the phenolate
leaving group (reviewed in references 22 and 95). Consistent
with its role as a general acid catalyst, the substitution of
Asp181 for an alanine allows phosphorylated substrates to
form stable complexes with the enzyme. This “substrate-trap-
ping” mutation has been used to enable isolation and identi-
fication of PTP substrates in vitro and in vivo (20, 23, 89, 94).
The Asp181-to-alanine mutation creates a more efficient sub-
strate trap than the mutation in which the active site Cys215 is
changed to serine or alanine, possibly because the former mu-
tation promotes the hydrophobic properties of the active site
cleft and removes the potential for electrostatic repulsion be-
tween the Asp181 and the phosphate moiety of the substrate
(23, 94).
As can be seen from the alignment in Fig. 1, the WPD loop
is strictly conserved among PTP domains but not among do-
mains D2 of RPTPs. Of the RPTPs with a single PTP domain,
only PTP-IA2 and PTP-IA2 have accepted non conservative
substitutions within the WPD motif, and the substrate trapping
alanine mutation (20) occurs naturally in PTP-IA2. Since cat-
alytic activity has not been shown for IA2 in vitro, it has been
suggested that its biological function is to compete with cata-
lytically active PTPs for specific substrates preventing their
dephosphorylation (49). The protein scaffold of PTP-IA2 could
be compatible with protein binding since two point mutations
in IA2 (Ala877Asp and Asp911Ala), which in PTP1B is equiv-
alent to the restoration of the general acid Asp181 in the WPD
loop and the canonical Ala217 in the PTP loop, is sufficient to
reconstitute catalytic activity towards myelin basic protein
phosphorylated on tyrosine (49). Another intriguing variation
of the WPD loop is observed in four human PTP catalytic
domains (PTPD1, PTPS31, PTP, and HDPTP) where a
longer glutamate residue replaces the general acid Asp181.
This is noteworthy because (i) the WPE loop variation is the
hallmark of domain D2 sequences, which usually account for
less than 0.1% of the total activity of the full-length enzyme
(24, 38, 68, 78, 90), and (ii) this replacement in PTP1B leads to
FIG. 1—Continued.














a reduction of up to 3 orders of magnitude in catalytic effi-
ciency (20, 90). It will be interesting to see whether these four
PTPs have diminished enzyme activity compared to enzymes
containing a general acid aspartate residue. However, recon-
stitution of the WPD motif in domain D2 of RPTP is not
sufficient to increase its catalytic activity to a level comparable
to that of domain D1, indicating that there are structural dif-
ferences other than the general acid-base among PTP domain
D1 and D2 (90) (see below).
Catalytic-water motif or Q loop (motif 10). In the
QTXXQYXF motif (M10), two glutamine residues (Gln262
and Gln266) and two conserved arginine residues (Arg254 and
Arg257) N terminal to this motif form crucial hydrogen bonds
with interacting residues of the PTP loop and its amide back-
bone. In particular, Gln262 positions and activates an active
site water molecule involved in the second hydrolysis step of
the phosphocysteine enzyme complex (61, 100). Enzyme ki-
netic analysis of the Yersinia PTP combined with site-directed
mutagenesis have revealed that Gln446 (equivalent to Gln262
in PTP1B) and, to a lesser extent, Gln450 (equivalent to
Gln266 in PTP1B) is responsible for restricting phosphoryl
transfer from the phosphoenzyme intermediate to water and
not to other nucleophile acceptors (i.e., preventing the phos-
phoenzyme intermediate from acting as a kinase phosphory-
lating undesirable substrates [100]). Notably, within this highly
variable area of the PTP structure (Fig. 5), only these arginine
and glutamine residues are invariant, consistent with their in-
volvement in catalysis (74, 100) and critical hydrogen bonding
with residues of the PTP loop (80).
Conservation of surface-exposed amino acids in vicinity of
active site: comparison between cytoplasmic PTPs and RPTP
domains D1 and D2. In an attempt to reveal novel structure-
function relationships, we performed the C-regiovariation
score analysis on three subsets of PTP domains: (i) nontrans-
membrane PTPs, (ii) receptor-like D1, and (iii) receptor-like
D2 (Fig. 7A, B, and C). The crystal structure of PTP1B was
used as a template for the intracellular PTPs, whereas the
molecular surface conservation among the aligned RPTP do-
main D1 and D2 sequences was illustrated using the X-ray
crystal structure of PTP domain D1 (50). The interchange-
able use of the PTP catalytic domains of PTP1B and PTP for
the calculation of the C-regiovariation score values is justified
by the excellent overlay of their tertiary structure, with a root
mean square (RMS) deviation of 1.35 A˚ between the two
domains (the RMS deviations between other PTP domain ter-
tiary structures are given in the legend to Fig. 4). Although
FIG. 1—Continued.














FIG. 2 Classification of family of PTPs into 17 subtypes. Shown is an unrooted tree derived from the alignment of 113 vertebrate PTP domain
sequences (residue positions 1 to 279 in human PTP1B). The tree was drawn by the neighbor-joining method (73). The horizontal distance indicates
the degree of sequence divergence, and the scale at the top corner represents the number of substitution events (10 per 100 amino acids).
Seventeen PTP domain subtypes were identified from the phylogram: nine nontransmembrane subtypes (NT1 to NT9), five tandem receptor-like
subtypes (R1/R6, R2A, R2B, R4, and R5), and three single-domain RPTP subtypes (R3, R7, and R8 [subtype R8 is believed to be catalytically
inactive]). As a statistical test of the significance of sequence similarity within PTP subtypes, bootstrap values were calculated (values are at the
dendogram node). With the exception of the RPTP-like subtype (R3) and the tandem PTP domain supertype, all subdivisions were assigned
based on maximal bootstrap values (1,000). (A tree including the PTP domain D2 sequences can be viewed [http://science.novonordisk.com/ptp],
and the raw data files can also be retrieved in several standard GCG formats).














conserved residues converged around the active site for the
intracellular PTPs and for domain D1 of RPTPs (Fig. 7A and
B, respectively), the domain D2 sequences exhibited a much
greater variation in the vicinity of the active site (Fig. 7C).
Our analysis of domain D2 sequences revealed several in-
triguing aspects of tandem domain RPTPs. Thus, the domains
D2 align extremely well with the catalytically active PTP se-
quences (with CD45 accommodating an acidic insert of 20
amino acids; Fig. 1), yet all the domains D2 are phylogeneti-
cally distinct from domains D1 (i.e., D2 sequences do not
cluster together with D1 sequences in the phylogenetic tree but
define a separate subfamily of PTP domains (data available at
http://science.novonordisk.com/ptp). In fact, the sequence sim-
ilarity between domains D2 of LAR, RPTP, and RPTP

(subtype R2B) is even higher than that between the corre-
sponding domain D1 sequences (45). Since phylogenetic anal-
yses have shown that PTP domain duplication (occurring in
five out of nine RPTP subfamilies) happened very early in
evolution (59) it can be argued that there must be a separate
function of the membrane distal domain in order for these
amino acids to be conserved at the present level. Noticeably,
both regulatory (38) and substrate-binding (78) functions have
been proposed for these domains.
Most of the invariant amino acids in domain D1, which show
considerable substitution in domains D2, converge around the
active site. Therefore, it is noteworthy that only two point
mutations (which restore the equivalent of Tyr46 within the
NXXKNRY motif) and the general acid equivalent of Asp181
(within the WPD loop) are sufficient to confer a robust PTP
activity back to domain D2 of some RPTPs, including PTPs
(48), PTP (9, 47), and LAR (56). However, domains D2 of
other RPTPs, such as CD45, PTP, and RPTP, have addi-
tional critical substitutions in several amino acids in the PTP
signature motif and, therefore, are most likely to be truly
inactive (48) (Fig. 1). Nevertheless, the structural architecture
of the active site signature motif of domains D2 may still be
FIG. 3. Schematic representation of PTP family members. Determination of sequence similarity among PTP catalytic domains (Fig. 2) was used
to classify the PTP family of enzymes into nine nontransmembrane PTP subtypes (NT) and eight RPTP subtypes (R). Only the human PTPs are
listed, and a representative member of each subtype is shown. Synonyms and classifications of all vertebrate PTPs are given in Table 1. PTPs having
closely related catalytic domains also tend to be similar in overall structural topology.














TABLE 3. Proposed roles of conserved residues in vertebrate PTP domainsa
Motif
(residues in PTP1B) Conservation
Conservation
in 3D Proposed roles of residues
Motif 1
40–46 NXXKNRY
Medium pTyr-recognition loop: restricts substrate specificity to pTyr (Asn44, coordinates
Asn68 which links Arg257; Arg45, putative substrate binding site, electrostatic





Low Conserved secondary structure (1 sheet), surface exposed (Arg56, H bonds to





Medium Core structure (Tyr66, coordinates Asn44 through hydrogen bonding; Ile67, hy-
drophobic core cluster [residues 57, 67, 69, 82, 98]; Asn68, H bonds with




High Core structure surrounding PTP loop (Ile82, hydrophobic core cluster [residues
57, 67, 69, 82, 98]; Ala83, packs or surrounds the PTP loop; Gln85, H bonds
with highly buried water molecule; Gly86, packs or surrounds the PTP loop;




Medium Conserved secondary structure (2 helix) (Asp94, contributes to conserved sub-
domain at the “back side”; Phe95, energetically favored T-stacking arrange-
ment with invariant Trp96; Trp96, H bonds to backbone of invariant Tyr124;
Met98, hydrophobic core cluster [residues 57, 67, 69, 82, 98]; Trp100, contrib-




Medium Hydrophobic core structure (Ile107, hydrophobic core structure packs with in-
variant Trp96; Val108, hydrophobic core structure packs with invariant Trp96;




Low Hydrophobic core structure (Lys120, interacts with Asp181 [ligand induced];
Tyr124, H bonds with His214, stabilizing T-stacking arrangement with




Low WPD loop, surface exposed, movable, contains general acid (Trp179, center of
movable WPD loop, mediating motion of loop; Pro180, H bonds to NH2 of
Arg221, mediating motion of loop; Asp181, general acid catalyst; Gly183, en-
ergetically favorable in loop motion [acts as hinge]; Pro185, energetically fa-




High PTP loop surrounding active site Cys where seven successive main-chain nitro-
gens coordinate three phosphate oxyanions (Pro210, structural hydrophobic
core; His214, lowers pKa of Cys215; Cys215, nucleophile; Ser216, H bonds
with Tyr46 stabilizing its interaction with substrate; Ala217, phosphotyrosine
binding, nonpolar interaction with substrate phenyl; Gly218, phosphotyrosine
binding; Gly220, phosphotyrosine binding; Arg221, H bonds with phosphate




Low The Q loop: interaction with active site water molecule (Gln262, H bonds with
scissile oxygen and active site water molecule; Gln266, H bonds with active
site water molecule; Tyr267, defines 6 helix structure; Phe269, defines 6
helix structure)
261–269 (V/I/L)QTXXQYXF
a Motifs are numbered (M1 to M10) in order of appearance in the primary amino acid sequence alignment (Fig. 1). Amino acids are numbered according to human
PTP1B. Conserved residues were identified from our multiple-sequence alignment of 113 vertebrate PTP domains (available at http://www.science.nononordisk.com
/ptp), and domain D2 sequences were not used in these evaluations. Underscored bold letters represent invariant amino acids. Residues in bold letters are conserved
in 90% of the sequences, and nonbold letters represent 80% conservation. Sequence conservation of each motif was calculated according to (i) amino acid identity
(top sequence) and (ii) amino acid similarity (bottom sequence), where X represents any amino acid (Fig. 1). Consensus substitution groups are defined as follows: 1,
DN; 2, EQ; 3, ST; 4, KR; 5, FYW; 6, LIVM. Residue conservation in the immediate three-dimensional (3D) surroundings was determined using C-regiovariation score
analysis (Fig. 5).














sufficiently preserved to retain the capacity to bind phospho-
tyrosine-containing proteins. Thus, the function of domain D2,
at least for some PTPs, may be similar to that of other tyrosine-
phosphate recognition units, such as SH2 domains (62) and
phoshotyrosine binding domains (21). In this regard, the C-
regiovariation score analysis of the domain D2 sequences (Fig.
7C), with the highly variable molecular surface area surround-
ing the phosphate-binding site, would signify the preference
for divergent and probably highly selective protein binding
partners. Such a potential is illustrated by domain D2 of CD45,
which has been shown to be critical for interleukin-2 secretion
and substrate recruitment of TCR- (41).
Identification of conserved interface between domains D1
and D2 of RPTPs. When comparing the RPTP domains D1
and D2 sequences by using the X-ray crystal structure of
RPTP domain D1 as template (79), the encircled area 1 in
Fig. 7 was found to be highly conserved among RPTP domain
D2 sequences (Fig. 7C) but not among RPTP domain D1
sequences (Fig. 7B). Significantly, the residues in this area
(Fig. 1, boxed in yellow) were recently identified as the struc-
tural linker that constrains the relative orientation of the two
PTP domains in LAR (56). Although this is so far the only
report describing the X-ray crystal structure of the tandem
arrangement of PTP domains, our alignment reveals that this
structural linker is highly conserved among all tandem domain-
containing RPTPs, suggesting conservation in function. The
consensus motif for this four-residue linker is G[D/E]TE (Fig.
1, highlighted in yellow).
In addition to the structural linker, our C-regiovariation
score analysis of RPTP domains D1 and D2 identified addi-
tional conserved residues (Fig. 8B and C, encircled area II),
which were confined to the region of the PTP tertiary structure
that correlates with the interdomain interface revealed by the
X-ray crystal structure of LAR (56). Again, the C-regiovaria-
tion score analysis predicted the exact location of the interface
in domain D2, including hydrogen bonding polar residues and
conserved hydrophobic residues responsible for the extensive
van der Waals interactions and tight complementary fit de-
scribed for the interface between domains D1 and D2 of LAR
(56). For the PTP domains in Fig. 8B, the center of conserva-
tion is less focused on the exact residues involved in this in-
terface, but when the single-domain RPTPs (subtypes R3, R7,
and R8) were removed from the C-regiovariation score anal-
ysis, the conservation of this area in domain D1 became even
more apparent (not shown). Significantly, the lack of conser-
vation of this region for the nontransmembrane PTPs (Fig. 8A)
illustrates that this interface is unique to tandem domain
RPTPs (Fig. 8B and C).
Identification of novel conserved pocket on surface of PTP
domain opposite active site. In addition to the identification of
conserved regions surrounding the active site and at the inter-
face between domains D1 and D2 of RPTPs, the C-regio-
variation score analysis identified another focus of conserva-
tion that was confined to the area of the molecule opposite the
active site (Fig. 8A, B, and C, encircled area III). This surface-
accessible area of conservation extends above a shallow hydro-
phobic pocket formed by residues IIe57, Ala69, IIe82, and
Met98. These four residues have adopted a configuration that
accommodates extensive van der Waals interactions and only
one PTP (the Xenopus, mouse, and human orthologs of MEG2)
has accepted nonconservative changes to residues within this
pocket. In addition, residues from motif 2 (DXXRVXL) and
motif 5 (TXXDFWXMXW) contribute to this conserved mi-
croenvironment, which explains why this cluster of conserva-
tion can be identified only when the PTP chain fold is consid-
ered.
Size and physiochemical nature of conserved pocket is con-
sistent with recognition site for protein-protein interaction.
Statistical examination of protein-protein associations suggests
a central role for hydrophobic residues at interfacial regions
(40, 67). In terms of amino acid composition at protein-protein
domain interfaces, it has been noted that there is a preference
for larger, nonpolar residues, particularly aromatic amino ac-
ids, as well as a few key basic or acidic residues (87). Indeed,
FIG. 4. Crystal structures of vertebrate PTP domains show con-
served fold and consistent C-backbone trace. PTP1B (magenta),
RPTP (gray), RPTP (red), LAR (blue), SHP1 (green), and SHP2
(yellow) were aligned and superimposed using Quanta (Molecular
Simulations Inc.). For clarity, residues 280 to 298 (C terminal) of
PTP1B, 250 to 281 (N terminal) and 522 to 532 (C terminal) of SHP1,
and 2 to 218 (N terminal) of SHP2 were omitted from the figure, as
well as D2 of LAR. The calculated RMS deviations between all C
atoms between PTP1B and other PTPs are as follows: PTP, 1.35 A˚;
RPTP, 2.72 A˚; LAR D1, 2.78 A˚; SHP1, 3.14 A˚; and SHP2, 2.74 A˚.
For comparison, the RMS deviation between domains D1 and D2 of
LAR is 1.3 A˚. The X-ray structures are compared in their native open
conformation.
TABLE 4. Proposed roles of single conserved residues in vertebrate




amino acid identity Proposed roles of the residues
Ile19 E (80%) Definition of 2 helix structure
Glu115 E (100%) Conserved H bonds with Arg221
Arg156 R (80%) Definition of 10-sheet
Arg169 R (80%) Definition of 11-sheet
Leu192 L (80%) Definition of the 3-helix structure
Arg254 R (90%) H bonds with PTP loop
Arg257 R (100%) H bonds with PTP loop lowering pKa
of Cys215
a Conserved residues were identified from our multiple-sequence alignment of
113 vertebrate PTP domains. Underscored bold letters represent invariant res-
idues. Residues in bold letters are conserved in 90% of the sequences, and
non-bold letters represent 80% conservation.














from the alignment analysis, we observed that the conserved
residues residing on the rim and within the shallow pocket
(Fig. 8, encircled area III) are more hydrophobic and aromatic
than the remainder of the surface of the PTP molecule, with
several charged residues surrounding the hydrophobic pocket.
Therefore, the amino acid composition in this region of the
PTP molecule is consistent with the identification of a possible
novel site of interaction. The size of the solvent-accessible area
that appears conserved (i.e., the dark blue area) is 250 A˚2.
Usually, the area of protein-protein interaction surfaces are
larger (700 Å2), typically constituting from 7 to 30% of the
total surface area of a monomer (39, 87). However, extensive
additional surface area can be included in this putative inter-
action site of the PTP domain if the adjacent less-conserved
residues (i.e., the white area in Fig. 8) are considered in the
evaluation.
In conclusion, the regiovariation score analysis has led to the
identification of the catalytic active site, the conserved linker
between domains D1 and D2 as revealed by the X-ray crystal
structure of LAR, as well as the approximate surface area of
interaction between domain D1 and D2. In addition, our anal-
ysis highlights a focus of conservation on the surface of the
PTP domain opposite the active site. Although the conserva-
tion of this pocket may be of structural importance, it is tempt-
ing to speculate the existence of additional roles for this site in
effector interactions with other protein domains or signaling
molecules. However, mutational and functional studies of ap-
propriate PTP mutants will be necessary to corroborate the
significance of residues in this area of the PTP domain.
Identification of nonconserved residues surrounding active
site—implications for substrate recognition and inhibitor de-
sign. In addition to the identification of three-dimensionally
conserved regions, the C-regiovariation score analysis offers a
unique opportunity to identify areas in a protein family that are
less well conserved and therefore might indicate a specialized
function. As an example, analysis of areas in the proximity of
the active site of enzymes, here PTPs, may lead to the identi-
fication of putative substrate-binding pockets. Furthermore,
such analysis in conjunction with primary sequence alignments
FIG. 5. The HCSAGXGR and IAXQGP motifs reside within the most highly conserved microenvironment of the PTP structure. Residues
located within a highly conserved three dimensional space of the PTP structure are identified by peaks. The C-regiovariation score was calculated
using the alignment information in Fig. 1 and the tertiary structure of PTP1B as template. Neighboring residues were defined using a three-
dimensional 7-Å sphere of influence. Similar results were obtained for a 5- to 8-Å sphere and when using PTP, PTP, or SHP2 as templates for
C-regiovariation score analysis (results not shown).
FIG. 6. Core structures within the PTP domain are highly con-
served and surface loops between secondary structure elements are
least conserved. Shown is a ribbon diagram indicating the positions of
conserved motifs (M1 to M10) within the tertiary structure. The degree
of conservation was determined from C-regiovariation score analysis
of 37 aligned human PTP catalytic domains (see Fig. 5). Areas of
conservation (blue, most conserved; red, least conserved) are illus-
trated using the PTP1B catalytic domain as the representative tertiary
structure. Shown is the front view of PTP1B looking into the active site.
The catalytically essential Cys215 residue is shown in yellow.














may allow the identification of unique combinations of amino
acid residues that can be addressed in a structure-based design
of selective inhibitors.
At present, two PTPs have been cocrystallized with peptide
substrates, PTP1B (37, 74, 75) and SHP1 (91). Although sig-
nificant differences in the binding modes were observed (see
below), both studies show peptide binding to residues defined
by the 1/1 loop and the M10 motif (5-loop-6) (Fig. 1).
Some of these residues, such as Tyr46 and Gln262, are highly
conserved and hence likely to be involved in the binding or
catalysis of all phosphotyrosine substrates. However, other res-
idues are quite variable and are potentially responsible for
defining substrate selectivity. Significantly, our structural align-
ment analysis identifies at least four areas in proximity to the
active site which are nonconserved and for which involvement
in the recognition of peptides and small molecule ligands have
been documented in biochemical and crystallographic studies
(Fig. 9). Although no single residue in these areas appears to
be a unique hallmark of any particular PTP, the combination
of residues in these areas is unique and could consequently
represent a selectivity-determining region. This is probably
most apparent for the region defined by residues 47, 48, 258,
and 259 of PTP1B (Fig. 9). In agreement with this, we have
recently shown that residue 259 is a key determinant in sub-
strate recognition and catalysis (66). Thus, the residue at po-
sition 259 in PTP1B is a glycine, which forms the bottom of an
open cleft that creates access to a second binding pocket ad-
jacent to the active site. This structural feature in PTP1B,
together with the plasticity conferred by Arg47 in accommo-
dating either acidic residues at the P-1 and P-2 positions in the
substrate (as illustrated in the EGFR988-993 peptide) (37) or
hydrophobic residues at P-1 (75), explains why PTP1B is able
to accommodate a broad range of artificial peptide substrates
in vitro. In contrast, PTPs with bulky residues at the position
equivalent to 259 in PTP1B including RPTP and LAR show
more limited peptide recognition capacity in vitro. We have
shown recently by kinetic and X-ray crystallographic studies
that replacing the bulky Gln259 residue in PTP with a glycine
converts PTP into a PTP1B-like enzyme and vice versa (66).
However, in a physiological context, the presence of a glycine
at position 259 in PTP1B allows for high-affinity binding of
substrates, such as the activation loop of the insulin receptor,
which contain two adjacent phosphotyrosine residues (74).
Thus, the simultaneous engagement of the substrate phospho-
tyrosine residue in the active site and the adjacent phosphoty-
FIG. 7. PTP domains from cytoplasmic PTPs and RPTP domains
D1 and D2 show significant differences in their conservation of sur-
face-exposed amino acids. Shown is surface conservation (blue, most
conserved; red, least conserved) of PTP domains from nontransmem-
brane PTPs (A), RPTP domains D1 (B), and RPTP domains D2 (C).
Shown is the front view looking into the active site. C-regiovariation
score values for the cytoplasmic PTPs are illustrated using the X-ray
crystal structure of PTP1B with the catalytically essential Cys215 (yel
low) and epidermal growth factor receptor-derived peptide (green)
bound within the active site (closed conformation). For ease of com-
parison, C-regiovariation score values among RPTP domains D1 and
D2 sequences are illustrated using the X-ray crystal structure of
RPTP domain D1 (50). The EGFR peptide (green) is modeled in the
active site of RPTP for orientation using only a closed conformation
of the X-ray crystal structures. Amino acids are labeled according to
the residue position in human PTP1B with the equivalent residues in
RPTP given in brackets (A and B). The conserved four-residue struc-
tural linker located at the N terminus of domain D2 (encircled area 1
in panel C), and which constrains the relative orientation of tandem
PTP domains in LAR, is compared to the corresponding nonconserved
area for the RPTP domain D1 sequences (encircled area 1 in panel B).
The amino acid residues defining this conserved linker are boxed and
colored yellow in the alignment in Fig. 1.














rosine residue at a second substrate-binding pocket may make
an important contribution to the substrate recognition by
PTP1B in vivo.
The most important residues in this second phosphotyrosine
binding site of PTP1B appear to be Arg24 and Arg254. Al-
though Arg254 is a highly conserved residue, the presence of
Arg24 and Gly259 seems to be unique to PTP1B and TC-PTP.
The tethering together of a ligand that simultaneously occupies
the active site with a ligand that interacts with residues of this
second phosphotyrosine binding pocket has been suggested as
a paradigm for PTP1B inhibitor design (69) resulting in re-
markably selective bis(aryldifluorophosphonate) inhibitors of
PTP1B (81). Furthermore, and consistent with this paradigm,
Ramachadran and colleagues have recently reported that pep-
tides containing two nonhydrolyzable analogs of phosphoty-
rosine [difluoro(phospho)methyl-phenylalanine] were potent
and specific inhibitors of PTP1B, illustrating that exquisite
substrate and inhibitor selectivity exists in close vicinity to the
active sites of PTPs (15).
In addition, other areas in the proximity of the active site
show considerable variability and could potentially be involved
in defining substrate specificity (Fig. 9). One such area is de-
fined by 5-loop-6 (i.e., between the M6 and M7 motifs).
Whereas no substrate binding has been observed in this region
in PTP1B, a study of SHP1 that had cocrystallized with two
different synthetic peptides revealed significant interaction
within this region, in one case due to salt bridge formation
between AspP-4 in the peptide substrate and Arg360 in SHP-1
(corresponding to S118 in PTP1B) (91). Interestingly, this re-
gion is quite different in SHP2. Therefore, these X-ray crystal-
lographic studies provide structural support for the observed
different substrate specificities of these closely related SH2
FIG. 8. Identification of novel conserved area on surface of PTP
domain opposite active site. Shown are surface conservation (C-
regiovariation score values) among nontransmembrane PTPs (A),
RPTP domains D1 (B), and RPTP domains D2 (C). The tertiary
structure is rotated 180° compared to structures in Fig. 7, showing the
surface of the molecule opposite the active site. Encircled area II (B
and C) corresponds to the interface for domains D1 and D2 as re-
vealed in the X-ray crystal structure of LAR (56). Encircled area III is
a novel putative interactive site, which appears to be conserved in all
three subsets of PTP domain sequences. Amino acids are labeled
according to the residue positions in PTP1B (A) and RPTP (B and C).
FIG. 9. Nonconserved amino acids in the proximity of the PTP
active site are involved in the recognition of PTP substrates and non-
peptide PTP inhibitors. Shown is the visualization of four selectivity-
determining regions on the molecular surface of PTP1B. Areas of
conservation (blue, most conserved; red, least conserved) represent
the C-regiovariation score values of 37 aligned human PTP catalytic
domains (values from Fig. 5). The amino acids involved in defining
these four selectivity-determining regions are indicated (boxed) in the
alignment in Fig. 1.














domain-containing PTPs, as demonstrated in two elegant cat-
alytic-domain-swapping experiments (60, 82). Although no di-
rect interaction has been observed in the crystal structure of
PTP1B complexed with peptide substrates, computational
studies suggest a similar role of this region in substrate recog-
nition by PTP1B (64). However, for the SHP1 cocrystal, it
should be noted that binding of peptide substrate to the PTP
catalytic domain did not bring the WPD loop into its closed
conformation (91), thus raising the question of whether it is a
catalytically competent complex.
Since such unique aspects of the structure in the vicinity of
the active site contribute to substrate specificity, we investi-
gated whether selective nonphosphonate, nonpeptide inhibi-
tors of PTP1B could be obtained by addressing one of these
regions. Our attention was directed to Asp48 and Arg47 in
PTP1B. As a starting point, we used a general PTP inhibitor,
2-(oxalylamino)-benzoic acid, which we had identified by high-
throughput screening of the Novo Nordisk compound library.
We reasoned that a correctly positioned basic nitrogen in the
inhibitor would be able to form a salt bridge with the side chain
of Asp48 in PTP1B, whereas an asparagine, which is found in
the equivalent position in many other PTPs, would cause re-
pulsion (Fig. 1). Indeed, a low-molecular-weight, nonphospho-
rus compound containing such a basic nitrogen displayed a
remarkable selectivity for PTP1B (36). Recently, studies with
PTP1B knockout mice (17, 44) and PTP1B antisense oligonu-
cleotides have provided compelling evidence that inhibition of
PTP1B may be an effective approach for the treatment of
diabetes and obesity (53). The identification of selectivity-de-
termining regions suggests that it may be possible to generate
specific inhibitors of PTP1B for use in this context. Further-
more, it is now becoming apparent that the inhibition of other
members of the PTP family may offer novel strategies for
therapeutic interaction in various human diseases. We hope
that the analysis presented here will not only assist in further
characterization of the PTP family but also may contribute to
the development of selective inhibitors of other potential drug
targets within the PTP family.
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